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ABSTRACT
Regulation of expression of the CFTR gene is poorly
understood. Elements within the basal promoter of
the gene do not fully explain CFTR expression pat-
terns, suggesting that cis-regulatory elements
are located elsewhere, either within the locus or in
adjacent chromatin. We previously mapped DNase I
hypersensitive sites (DHS) in 400kb spanning the
CFTR locus including a cluster of sites close to the
3’-end of the gene. Here we focus on a DHS at
+6.8kb from the CFTR translation end-point to eval-
uate its potential role in regulating expression of the
gene. This DHS, which encompasses a consensus
CTCF-binding site, was evident in primary human
epididymis cells that express abundant CFTR
mRNA. We show by DNase I footprinting and elec-
tophoretic mobility shift assays that the cis-regula-
tory element within this DHS binds CTCF in vitro.
We further demonstrate that the element functions
as an enhancer blocker in a well-established
in vivo assay, and by using chromatin immunopreci-
pitation that it recruits CTCF in vivo. Moreover,
we reveal that in primary epididymis cells, the
+6.8kb DHS interacts closely with the CFTR pro-
moter, suggesting that the CFTR locus exists in a
looped conformation, characteristic of an active
chromatin hub.
INTRODUCTION
The cystic ﬁbrosis transmembrane conductance regulator
(CFTR) gene is located at chromosome 7q31.2, where it
is ﬂanked upstream by ASZ1 (ankyrin repeat, SAM
and basic leucine zipper) and downstream by CTTNBP2
(cortactin binding protein 2). These neighbouring genes
have very diﬀerent expression proﬁles: CFTR is expressed
primarily in specialized epithelial cells (1–3), while ASZ1
is transcribed exclusively in the testis and ovary (4), and
CTTNBP2 is highly expressed in the brain, kidney and
pancreas, with lower levels of expression in other tissues
(5). We previously identiﬁed two enhancer-blocking insu-
lators 50 and 30 to the CFTR gene that had distinct proper-
ties. First, a DNase I hypersensitive site (DHS) located
at  20.9kb with respect to the translation start site was
associated with a classical CTCF-dependent insulator ele-
ment (6). CTCF, a ubiquitously expressed, zinc ﬁnger
DNA-binding protein (7,8) often establishes indepen-
dently regulated domains of gene activity. A second ele-
ment, located 30 to CFTR, within a DHS at +15.6kb also
demonstrated enhancer-blocking activity but this was
independent of CTCF-binding. The +15.6kb DHS was
marked by a peak of euchromatin-speciﬁc histone modiﬁ-
cations, unlike the  20.9kb DHS (6), supporting the
hypothesis that these elements function by diﬀerent
mechanisms.
CFTR exhibits tightly regulated expression, both
temporally during development, and spatially in diﬀerent
tissue types (1,9,10). However, somewhat paradoxically,
the CFTR promoter resembles that of a house-keeping
gene, in that it is CpG rich, contains no TATA box, has
multiple transcription start sites and has several putative
binding sites for the transcription factor Sp1 (11).
Consistent with promoters of this type, the CFTR pro-
moter demonstrates no apparent tissue-speciﬁcity, sug-
gesting the involvement of distal regulatory elements in
control of CFTR expression. It is probable that these ele-
ments are associated with DHS across 400kb encompass-
ing the CFTR locus (12–15). In addition to the prominent
site at +15.6kb other DHS were evident 30 to the coding
region of the gene, in particular, a complex cluster of sites
at +5.4kb, +6.8kb, +7.0kb and +7.4kb from the
CFTR translation end-point (13). The DHS at +5.4kb
and +7.0kb were observed in a variety of cell types, irre-
spective of CFTR expression; however, the DHS at
+6.8kb and +7.4kb were only found in a restricted
number of CFTR-expressing cell-types, including primary
epididymis cells, suggesting that they may contain
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trolling CFTR-expression (13).
Here we demonstrate that the +6.8kb DHS is asso-
ciated with a tissue-speciﬁc CTCF-binding site that dis-
plays enhancer-blocking activity comparable to that of
other known insulator elements, including the one at the
CFTR  20.9kb DHS. CTCF is thought to be involved in
regulating nuclear organisation and CTCF-dependent
chromatin loops exist (16–18), which may depend on
tethering to the nuclear matrix (19,20) and/or association
with cohesins (21–23). Hence, we next evaluated the three-
dimensional structure of the CFTR locus in primary cells
that exhibit the +6.8kb DHS and express CFTR. Using
chromosome conformation capture (3C), we demonstrate
that a region encompassing the +6.8kb DHS shows
strong interaction with the CFTR promoter in these
cells. We predict that looping of CFTR, possibly induced
by CTCF, enables key regulatory elements at the 30-end of
the gene to move into close proximity with the CFTR
promoter, so activating cell-type-speciﬁc expression.
MATERIALS AND METHODS
Cell culture
The K562 erythroleukemia cell line (24) was cultured in
RPMI 1640 supplemented with 10% fetal calf serum
(FCS). The Caco2 (25) cell line was cultured in DMEM
supplemented with 10% FCS. Primary human fetal male
epididymis cells (26) were cultured in CMRL1066
medium, 15% FCS, supplemented with hydrocortisone,
insulin and cholera toxin. Human skin ﬁbroblasts
(GM08333) were cultured in MEM medium with
15% FCS.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out
following the Upstate protocol with minor modiﬁcations.
Brieﬂy, 5 10
7cells were crosslinked with 1% formalde-
hyde for 10min at room temperature. Crosslinking was
stopped by the addition of Glycine to 0.125M. Cells
were washed in cold phosphate-buﬀered saline (PBS) con-
taining protease inhibitors (Roche) and lysed in 1ml of
1% SDS, 10mM EDTA, 50mM Tris–HCl (pH 8.1) plus
protease inhibitors. Sonication was carried out to produce
fragments of 1kb or under.
Immunoprecipitations were performed overnight at 48C
with 10ml of a CTCF-speciﬁc antibody (Upstate 07-729)
and 200ml of chromatin (corresponding to 1 10
7cells),
and complexes were collected with protein A agarose
beads for 1h. No antibody samples were prepared, in
which chromatin was incubated with protein A agarose
beads alone. Immunoprecipitations were washed, DNA
eluted and cross-links reversed according to the Upstate
protocol.
All immunoprecipitations were performed in duplicate
or triplicate. Immunoprecipitated and 1/10 diluted input
DNA samples were used as templates for Taqman qPCR.
Primer and probes sets corresponding to regions of inter-
est within the CFTR locus were designed using primer
express 1.0 software (Supplementary Data) and obtained
from Eurogentec or IDT. Reactions were carried out fol-
lowing the ABI protocol and performed in triplicate.
Enhancer-blocking activity assay
The plasmids pNI and pNI-FII were a kind gift from the
Felsenfeld group (27). Enhancer-blocking assays were per-
formed as previously described (27,28). G418-resistant
colonies were counted after 2–3 weeks of selection and
data subjected to statistical analysis by one-way
ANOVA followed by Dunnett’s multiple comparison test.
Electrophoretic mobility shift assays (EMSAs)
Caco2 nuclear extracts were prepared by standard meth-
ods (29). In vitro translated (IVT) CTCF was made by
in vitro transcription and translation of pCTCF (30)
using the TNT-Kit (Promega) and following manufac-
turer’s instructions. EMSA experiments were carried out
as described previously (6). Antibody supershift reactions
were performed using anti-CTCF (Upstate 07-729) or
anti-RARa (sc-773 ).
Invitro DNase I footprinting
The +6.8kb DHS was PCR-ampliﬁed using primers
6.8B-F (AAGAACATTATGAAAGGTGGTC; AC00
0061: 64235–64256) and 6.8B-R (AAGATAAAATGTC
TTTGAGATT; AC000061: 64510–64489), and then
cloned into pCRscript (Invitrogen). Following excision
by either EcoRV/NotI or ClaI/SacII digestion, Klenow
DNA polymerase ﬁll-in with [a-
32P]-dCTP was used to
label either the sense or anti-sense strand, respectively.
DNase I footprinting reactions were performed as
described previously (31).
Chromosome conformation capture (3C)
3C was performed as described previously (32,33), with
minor modiﬁcations. Brieﬂy, 1 10
7cells were ﬁxed with
2% formaldehyde for 10min at room temperature. Cells
were lysed in 5ml cold lysis buﬀer [10mM Tris (pH 8),
10mM NaCl, 0.2% NP-40, 1  protease inhibitor cocktail
(Roche)] and the nuclei collected by centrifugation.
Following extraction with 0.3% SDS, chromatin was
digested overnight with 2000U HindIII. Ligations were
performed in a total reaction volume of 6.5ml, using
100U T4 DNA ligase (Roche) and incubation at 148C
for 4h followed by 30min at room temperature. Cross-
links were reversed by proteinase K treatment at 658C
overnight. Samples were puriﬁed by phenol–chloroform
extraction followed by ethanol precipitation, and then
re-suspended in 150mlH 2O. The concentration of each
sample was determined by SYBR green qPCR, using the
B13F/B13R primer set (amplicon found within a HindIII
fragment; see Supplementary Data) and comparison to a
genomic DNA reference of known concentration. Samples
were subsequently diluted to a concentration of 100ng/ml.
A Taqman probe and reverse primer was designed
that was speciﬁc to a HindIII fragment at the bait
region of interest (i.e. the CFTR promoter). Multiple for-
ward primers were then designed that were each speciﬁc
to diﬀerent HindIII fragments across the CFTR locus
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and locations). Using a dilution series of digested/
re-ligated BAC DNA template, each forward primer was
demonstrated to function with the ‘ﬁxed’ Taqman probe
and reverse primer to amplify with 100% eﬃciency. To
quantify ligation events within 3C samples, 200ng of 3C
template was used per 20ml Taqman qPCR reaction. The
ligation eﬃciency (or ‘interaction frequency’) between
each fragment and the CFTR promoter was corrected
for the interaction between two HindIII fragments
within the ubiquitously expressed excision repair cross-
complementing rodent repair deﬁciency, complementation
group 3 (ERCC3) locus, which has been reported to
adopt the same spatial conformation in diﬀerent tissues
(16,34,35).
RESULTS
A cluster of four DHS was previously identiﬁed at the
30-end of the CFTR gene, at +5.4kb, + 6.8kb, +7.0kb
and +7.4kb from the CFTR translation termination site
(13). The DHS at +5.4kb and +7.0kb were observed in a
variety of cell types, irrespective of CFTR expression;
however, the DHS at +6.8kb and +7.4kb were only
found in a restricted number of CFTR-expressing cell-
types, including primary human epididymis cells.
Apredicted CTCF-binding sitewithin the +6.8kbDHS
corresponds toa60-bp DNaseI footprint
An in silico search for regulatory factors that could bind
to the +5.4kb, +6.8kb, +7.0kb and +7.4kb DHS
regions of the CFTR locus (AC000061 62735–65135),
revealed a site within the +6.8kb DHS region that
matched the consensus sequence for CTCF binding
(7,30) at 13 out of 14bp (AC000061 64412–64399)
(Table 1).
A 275-bp fragment spanning the +6.8kb DHS
(AC000061 64235–64510) was labelled at the 30-end of
either the sense or the anti-sense strand and used as a
template for DNase I footprinting. In the presence of
Caco2 cell nuclear extract, the +6.8kb DHS sense
strand exhibited protection from DNase I digestion
(PR1) over 60bp, at AC000061 64373–64436 (Figure 1A
and Supplementary Figure 1). A weaker protected region
was also evident at the corresponding location on +6.8kb
DHS anti-sense strand (Figure 1B). Extensive DNase I
footprints are characteristic of those produced by CTCF
binding (36), and furthermore, the putative site of
interaction with CTCF identiﬁed in silico was centrally
positioned within PR1 (Figure 1).
CTCF binds to the+6.8kbDHSsequence in vitro
In vitro binding of CTCF at the putative +6.8kb DHS-
binding site (PR1), was investigated by EMSA. A 78-bp
oligonucleotide probe, DHS6.8
oligo, was generated that
spanned the putative +6.8kb DHS CTCF-binding
site (Figure 2A and Supplementary Figure 1).
DHS6.8mut
oligo, had the same sequence with the excep-
tion of alterations in the 14-bp putative CTCF-binding
site core which was positioned centrally within
DHS6.8
oligo (Figure 2A). EMSA experiments with the
DHS6.8
oligo probe demonstrated that this sequence binds
IVT CTCF (Figure 2B, i) and that the complex formed
was supershifted with an antibody speciﬁc to CTCF
(Figure 2B, ii), but not an isotype control antibody
(anti-RARa). DHS6.8
oligo also formed a complex with
Caco2 nuclear extract that was of the same mobility
as that formed with IVT CTCF (Figure 2C, i). The com-
plex formed between DHS6.8
oligo and Caco2 nuclear
extract was competed by unlabelled self, but not by
DHS6.8mut
oligo (Figure 2C). The complex was also com-
peted by FII (a known CTCF-binding site from the
chicken  -globin locus), but not by a mutant version of
this probe (FII mut) (Figure 2C). Furthermore, the com-
plex formed between DHS6.8
oligo and Caco2 nuclear
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Figure 1. In vitro DNase I footprinting of the +6.8kb DHS probe.
Experiments using (A) sense and (B) anti-sense strands are shown. Both
gel images are labelled as follows: 1, AG ladder; 2, No DNase I; 3, No
Caco2 nuclear extract; 4 and 5, 40mg and 80mg Caco2 cell nuclear
extract, respectively. For both panels, protected region 1 (PR1) is high-
lighted by a bold vertical line. Narrow vertical line marked with an
asterisk shows position of putative CTCF-binding site.
Table 1. Potential CTCF-binding site within the +6.8kb DHS region
Sequence
(CTCF consensus) C C G C n n G G n G G C A G
+6.8kb DHS C C a C a a G G t G G C A G
The CTCF consensus (7,30) is shown at the top of the table followed
by the putative binding site within the +6.8kb DHS. Bases shaded in
grey indicate matches to the consensus.
1088 Nucleic Acids Research, 2009, Vol. 37,No. 4extract was also supershifted by an antibody speciﬁc to
CTCF (Figure 2D, ii), but not by an isotype control anti-
body. When the DHS6.8mut
oligo probe was used in EMSA
experiments, the CTCF complex was not observed with
either Caco2 nuclear extract (Figure 2E) or IVT CTCF
(data not shown). In the presence of Caco2 nuclear
extract, DHSmut
oligo exhibited two weak complexes (
 ),
possibly due to CTCF site mutation creating novel tran-
scription factor binding sites. However, given the lack
of interaction between DHS6.8mut
oligo and IVT CTCF,
these novel complexes are likely to involve proteins
other than CTCF.
These data conclusively demonstrate a strong in vitro
interaction between the +6.8kb DHS region and CTCF.
CTCF binds to the+6.8kbDHSin vivo
Since CTCF showed a strong interaction with DHS6.8
oligo
in vitro, ChIP with an antibody speciﬁc for CTCF fol-
lowed by Taqman quantitative PCR analysis was used
to investigate in vivo binding at this site. Chromatin
from two cell types was evaluated: Caco2 colon carcinoma
cells and fetal male primary epididymis cells, both of
which express abundant CFTR. For Caco2 chromatin,
ChIP with an antibody speciﬁc to CTCF gave an
 5-fold enrichment of the +6.8kb DHS relative to a
region within CFTR intron 17a where there is no predicted
CTCF-binding site (Figure 3A). The +15.6kb DHS of
CFTR (located  9kb 3 0 to the +6.8kb DHS), that was
previously demonstrated to possess CTCF-independent
enhancer-blocking activity, showed no CTCF-speciﬁc
enrichment, consistent with our earlier work (6). In con-
trast, using primary epididymis chromatin, the CTCF-
speciﬁc antibody enriched the +6.8kb DHS region by
about 15-fold relative to CFTR intron 17a (Figure 3B).
Approximately 2.5kb either side of the +6.8kb DHS, at
+4.4kb and +9.3kb relative to the CFTR translation
end-point, CTCF-speciﬁc enrichment in primary epididy-
mis cells returned to baseline levels. The +15.6kb DHS
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Figure 2. In vitro binding of CTCF at the +6.8kb DHS region. (A) The DHS6.8
oligo and DHS6.8mut
oligo probes. The putative CTCF-binding site
core is highlighted. Oligonucleotides were designed to form BssHII sticky ends when annealed (shown in italics), facilitating cloning into the AscI site
of pNI. Mutated bases in DHS6.8mut
oligo are underlined. (B) IVT CTCF; (C, D), Caco2 nuclear extracts. (B) EMSA using DHS6.8
oligo. Supershift
was performed with an anti-CTCF antibody and anti-RAR   was used as isotype control. (C) EMSA with DHS6.8
oligo. Competition reactions were
performed with 100  excess of unlabelled DHS6.8
oligo (self), DHS6.8mut
oligo (self mut), FII (known CTCF-binding site from chicken  -globin locus)
and mutant (FIImut). (D) EMSA with DHS6.8
oligo. Supershift reactions were performed as in (B). (E) EMSA with DHS6.8mut
oligo. Complex marked
i represents CTCF in complex with DHS6.8
oligo and ii the antibody-supershifted CTCF complex. Undeﬁned interactions formed between 6.8mut
oligo
and Caco2 nuclear extract are marked by
 .
Nucleic Acids Research,2009, Vol.37, No. 4 1089again showed no CTCF-speciﬁc enrichment in epididymis
chromatin. For both Caco2 and primary epididymis chro-
matin, negative control ChIP experiments in which
chromatin was immunoprecipitated with protein A
beads alone (no antibody) resulted in baseline levels of
enrichment at all regions (data not shown). Taken
together, these results demonstrate strong in vivo binding
of CTCF at the +6.8kb DHS in primary epididymis cells,
with a much lesser interaction between CTCF and the
+6.8kb DHS in the Caco2 cell line. It is noteworthy
that CTCF-speciﬁc enrichment of the +6.8kb DHS in
primary epididymis cells correlates with the presence of
the +6.8kb DHS in this cell type (13).
In addition to the CTCF-binding site that we deter-
mined experimentally at the +6.8kb DHS, another
CTCF-binding site was predicted in silico at the 30-end
of the CFTR locus, (7). This site is located at +2.9kb
from the CFTR translation end-point (AC000061:60371–
60384) and has a 12 out of 14-bp match with the CTCF
consensus. To evaluate CTCF-speciﬁc enrichment of this
region in Caco2 and primary epididymis cells, an addi-
tional Taqman primer/probe set was designed. Both
Caco2 and primary epididymis cells showed only modest
CTCF-speciﬁc enrichment of the +2.9kb region ( 4- and
5-fold, respectively) (Figure 3A and B) in comparison
to 15-fold enrichment at the +6.8kb site in epididymis
chromatin. Moreover, the lack of any known DHS
at this region in these cell types brings into question the
biological signiﬁcance of the +2.9kb predicted CTCF-
binding site.
Enhancer-blocking activity at the+6.8kbDHS
Binding of CTCF is necessary for enhancer-blocking
activity at the majority of vertebrate insulator elements
(37,38). Since the +6.8kb DHS binds CTCF, and is
located in an intergenic region, we used a well-established
assay (27,28) to investigate whether this element possessed
enhancer-blocking activity. This test uses the pNI plasmid,
in which the mouse HS2 enhancer of the  -globin LCR
is positioned upstream of a neo
r gene driven by the human
g-globin promoter. Sequences to be assayed for insulator
activity are cloned into a unique AscI site located between
the enhancer and promoter. Transfection of these con-
structs into K562 human erythroleukemia cells yields
G418-resistant colonies, with a frequency dependent
on the level of enhancer-promoter communication (and
hence enhancer-blocking activity of the intervening
fragment).
The DHS6.8
oligo and DHS6.8mut
oligo oligonucleotides
were designed with BssHII sticky ends (Figure 2A), facil-
itating their direct cloning into the AscI site of pNI. An
enhancer-blocking activity assay was performed, with the
number of neomycin-resistant colonies obtained for each
construct normalized to the empty pNI plasmid. Results
were subjected to statistical analysis by one-way ANOVA
followed by Dunnett’s multiple comparison test. When
inserted into the enhancer-blocking position of pNI,
FII, the CTCF-binding core from the known 50HS4
chicken  -globin insulator (28,37), signiﬁcantly reduced
the number of colonies (2- to 3-fold; P<0.01)
(Figure 4). The pNI-DHS6.8
oligo construct also gave a
signiﬁcantly lower number of colonies compared to pNI
(2- to 3-fold, P<0.01). In contrast, although the pNI-
DHS6.8mut
oligo construct gave a slightly lower number
of colonies than pNI, this was not signiﬁcant (P>0.05).
This suggests that CTCF binding at the +6.8kb DHS is
responsible, at least in part, for the enhancer-blocking
activity of this element.
As some CTCF-binding sites are associated with
silencer activity (39), we investigated this possibility for
the CFTR +6.8kb DHS CTCF-binding site. A modiﬁed
version of DHS6.8
oligo was generated with NdeI sticky
ends (as opposed to BssHII), enabling DHS6.8
oligo to
be cloned into an NdeI site upstream of the HS2 enhancer
(as shown in Figure 4). However, in this arrangement,
DHS6.8
oligo had no signiﬁcant eﬀect upon colony
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Figure 3. In vivo binding of CTCF at the +6.8kb DHS region. Immunoprecipitations were performed with a CTCF-speciﬁc antibody and chromatin
from (A) Caco2 cells and (B) Primary epididymis cells. No antibody control samples were also prepared, in which chromatin was incubated with
Protein A agarose beads alone (data not shown). Samples were subjected to Taqman quantitative PCR analysis using probes speciﬁc for intron 17a
and regions of interest 30 to CFTR. CTCF-speciﬁc enrichment of each of these regions is shown relative to levels at intron 17a (which contains no
predicted CTCF-binding sites). Vertical dashed line represents location of CFTR translation end-point, and x-axis on the right of this is drawn to
scale (i.e. each data point accurately reﬂects the relative positions of Taqman amplicons). Immunoprecipitations were repeated at least twice. PCRs
were performed in triplicate and Ct values averaged. Error bars denote S.E.M.
1090 Nucleic Acids Research, 2009, Vol. 37,No. 4number (P>0.05) (see 6.8NdeI, Figure 4). This demon-
strates that the enhancer-blocking activity of the CFTR
+6.8kb DHS is directional (in that it only has an eﬀect
when positioned between an enhancer and promoter),
consistent with this element being an insulator rather
than a silencer (27).
Looping of theCFTR locus inCFTR-expressing cell types
CTCF sites that ﬂank the  -globin locus interact with the
promoters of actively expressed globin genes, bringing
them within proximity of the  -globin ‘active chromatin
hub’ (ACH) (16–18). Within the CFTR locus, in addition
to the 30 CTCF-binding site at +6.8kb investigated here,
we previously characterized a CTCF-binding site 50 to the
locus in the  20.9kb DHS region (6). The presence of
these two DHS ﬂanking the locus suggested similarities
to  -globin. Hence we investigated whether either of the
CTCF sites that ﬂank CFTR interacts with the CFTR
promoter region using chromosome conformation capture
(3C) (33).
Formaldehyde-crosslinked nuclei from human primary
skin ﬁbroblasts (CFTR non-expressing) and human
primary epididymis epithelial cells (CFTR-expressing)
were subjected to HindIII digestion and subsequent 3C
analysis. A ﬁxed Taqman probe and reverse primer
were designed within a HindIII fragment at the CFTR
promoter, and multiple forward primers were
generated within distal regions across the CFTR locus
(Figure 5A and Supplementary Data). These forward
primers were located within HindIII fragments encom-
passing the  20.9kb, +6.8kb and +15.6kb DHS,
and within speciﬁc intronic HindIII fragments. The
assay fragments were positioned  25 to 50kb apart,
such that they would give a good overall representa-
tion of the structure of the CFTR locus (Figure 5A).
Real-time PCR reactions using the ‘ﬁxed’ reverse probe/
primer and each of the ‘variable’ forward primers
enabled quantiﬁcation of ligation events (subsequently
referred to as ‘interaction frequency’) between the CFTR
promoter and speciﬁc distal regions within each 3C
sample.
Within primary human skin ﬁbroblasts, which do not
express CFTR, interaction frequency with the CFTR
promoter decreased as a function of distance from the
promoter, with no signiﬁcant interaction between the
CFTR promoter and either the  20.9kb or +6.8kb
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Figure 5. 3C analysis of the CFTR locus. (A) Scale ﬁgure of the CFTR
gene with exons marked by vertical bars and the translation start site
represented by a bent arrow. Small vertical lines above the gene denote
HindIII sites and half arrow heads show the locations of 3C primers.
Due to space constraints, primers are not drawn to scale, and the ﬁxed
CFTR promoter HindIII fragment is expanded, showing the location of
Taqman probe (joined ball and star) and the reverse primer. The –
20.9kb DHS and +6.8kb DHS locations are also indicated. (B)3 C
data from primary human skin ﬁbroblast cells. (C) 3C data from pri-
mary human epididymis cells. The x-axis for each chart is drawn to
scale, with units representing base pairs relative to the CFTR transla-
tion start point (0). Both charts are aligned with the CFTR gene ﬁgure
above. Vertical dashed lines represent HindIII sites. The interaction
frequency between a ﬁxed HindIII fragment at the CFTR promoter
(shaded grey) and HindIII fragments at various regions across the
CFTR gene was measured by Taqman quantitative PCR. The interac-
tion frequency at each point is expressed relative to the interaction
between two HindIII fragments within the ubiquitously expressed
ERCC3 gene. Data shown represent the average of two independent
experiments. Each real-time PCR reaction was performed three times
and averaged. Error bars denote SEM.
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Figure 4. Enhancer-blocking activity at the +6.8kb DHS region. Each
construct used in the enhancer-blocking assay is depicted as follows:
pNI is the empty pNI plasmid and pNI-FII (FII) contains a known
insulator from the chicken  -globin locus (represented by a triangle).
pNI-6.8 (6.8) contains the wild-type DHS6.8
oligo (represented by a
rectangle) and pNI-6.8mut (6.8mut) contains the mutant version
DHS6.8mut
oligo (represented by a rectangle with a cross in it). pNI-
6.8NdeI (6.8NdeI) contains the wild-type DHS6.8
oligo sequence cloned
upstream of the HS2 enhancer (as opposed to between HS2 and the
g-neo reporter). The number of Neo
R colonies obtained for empty pNI
was given a value of 1, and the number of colonies obtained with all
other constructs was expressed relative to this value. Error bars denote
S.E.M. of triplicate experiments carried out on three separate occa-
sions, except for 6.8NdeI which was performed in triplicate on one
occasion. Diﬀerent plasmid DNA preparations were used for each
experiment within the triplicates.
  P<0.01.
Nucleic Acids Research,2009, Vol.37, No. 4 1091DHS (Figure 5B). Furthermore, there were no peaks of
interaction at any of the intronic locations assayed. These
data suggest that within CFTR-negative primary skin
ﬁbroblasts, the CFTR locus exists in a relaxed structure,
or at least one that does not contain stable loops that
bring distal regulatory elements close to the promoter.
In contrast to the skin ﬁbroblast data, in CFTR-expres-
sing primary epididymis cells, the CFTR locus exhibited a
3C proﬁle that suggested speciﬁc interactions between the
promoter and distal regions (Figure 5C). For example, a
moderate interaction was detected between the CFTR pro-
moter and a region within intron 19, possibly indicating
the presence of an intronic regulatory element that inter-
acts with the promoter. However, most signiﬁcantly, a
strong interaction frequency was detected between the
CFTR promoter region and a HindIII site at the 30-end
of the CFTR locus encompassing the +6.8kb DHS.
Indeed, despite being located more than 200kb from
the CFTR promoter region, this 30 fragment demonstrated
an interaction frequency with the CFTR promoter that
was greater than a HindIII fragment within intron 1 of
the CFTR, <10kb from the CFTR promoter (Figure 5C).
For the adjacent 30 fragment ( 210kb from the CFTR
promoter), interaction frequency fell dramatically to an
apparently baseline level, suggesting that the CFTR pro-
moter interacts speciﬁcally with elements in the HindIII
fragment encompassing the +6.8kb DHS.
Unlike the +6.8kb DHS, in primary epididymis cells,
no signiﬁcant interaction was detected between the CFTR
promoter and the  20.9kb DHS CTCF-binding site
(Figure 5C). The lack of interaction between these two
sites was also conﬁrmed using a  20.9kb DHS-speciﬁc
Taqman probe and reverse primer in combination with a
forwards primer speciﬁc to the CFTR promoter region
(data not shown). Furthermore, using the  20.9kb DHS
probe, no interaction was detected with the +6.8kb DHS.
These data indicate that within CFTR-expressing pri-
mary epididymis cells, the CFTR locus exists within a
looped structure, with a HindIII fragment encompassing
the +6.8kb DHS CTCF site being in close proximity
to the CFTR promoter. In contrast, at the opposite end
of the locus, no interaction is apparent between the
 20.9kb DHS CTCF site and the CFTR promoter.
DISCUSSION
Expression of the CFTR gene is tightly controlled, both
temporally during development and spatially in diﬀerent
tissue types. However, the underlying genetic mechanisms
responsible for conferring these complex CFTR expression
patterns are poorly understood. The CFTR promoter is
weak and demonstrates little tissue speciﬁcity, suggesting
that key regulatory elements must be located elsewhere
within the gene or in adjacent genomic regions. To identify
potential regulatory elements, we previously performed
DHS mapping in a variety of cell types, across 400kb
spanning the CFTR locus. Of the DHS that were found,
a subset showed some correlation with CFTR expression.
These included two DHS at the 30-end of the gene,
at +6.8kb and +7.4kb from the CFTR translation
end-point.
The +6.8kb DHS was only observed in fetal epididy-
mis cells and adult lung tissue, both CFTR-expressing pri-
mary cell types. Here we demonstrate that the +6.8kb
DHS contains a predicted CTCF-binding site with a
close match to the consensus. Moreover, this region
shows a strong in vivo association with CTCF in chroma-
tin extracted from primary epididymis cells, correlating
with the presence of the DHS in these cells. Although
we did not previously observe the +6.8kb DHS in
Caco2 colon carcinoma cells experiments with Caco2
chromatin showed slight CTCF-speciﬁc enrichment at
this site. It is thus possible that within a large population
of Caco2 cells, a small number of cells exhibit the
+6.8kb DHS.
While most CTCF-binding sites throughout the human
genome appear to be cell-type invariant, a fraction are
cell-type speciﬁc (7). This cell-type speciﬁcity may be con-
ferred by DNA methylation at CpG dinucleotides, an epi-
genetic mark that is known to aﬀect CTCF binding
(38,40). However, within the CFTR +6.8kb DHS, there
is an absence of CpG dinucleotides, with the nearest CpG
located about 200bp 50 to the CTCF-binding site core.
It therefore seems unlikely that tissue-speciﬁc control of
CTCF binding at the +6.8kb DHS is controlled by DNA
methylation, suggesting the use of a diﬀerent regulatory
mechanism. For example, it is possible that events leading
to the formation of the +6.8kb DHS, such as nucleosome
remodelling, may regulate CTCF binding.
Genome-wide analysis of CTCF binding in primary
human ﬁbroblast IMR90 cells revealed  14000 genomic
regions ﬂanked by CTCF-binding sites, so-called CTCF-
pair-deﬁned domains (CPDs) (7). Within these CPDs, the
average distance between CTCF-binding sites was found
to be 212090bp. It is therefore of interest that the CFTR
gene is contained within an apparent CPD of 214000bp,
considering the distance between the +6.8kb DHS and
the previously described  20.9kb DHS CTCF-dependent
insulator element (6).
At the  -globin locus, CTCF sites that ﬂank the locus
associate with actively transcribed globin promoters
within the  -globin active chromatin hub (ACH) (16–18).
In the present study, we demonstrated that there is no
association between the CFTR promoter and the
 20.9kb DHS CTCF-binding element in the upstream
ﬂanking region, irrespective of CFTR expression. In
contrast, in CFTR-expressing primary epididymis cells,
we observed a strong interaction between the CFTR
promoter and a region at the 30-end of the CFTR gene
encompassing the +6.8kb DHS CTCF-binding site.
This interaction was not seen in skin ﬁbroblast cells,
which do not express CFTR, suggesting that ‘looping’ of
the CFTR locus correlates with active expression of
the gene.
In addition to the +6.8kb DHS, the 30 HindIII frag-
ment demonstrated here to interact with the CFTR pro-
moter encompasses a number of other DHS. These
include the cluster of adjacent DHS (+5.4kb, +7.0kb
and +7.4kb) (13) and the previously characterized
+15.6kb DHS enhancer-blocking element (6). Within
1092 Nucleic Acids Research, 2009, Vol. 37,No. 4primary epididymis cells, the +6.8kb, +7.0kb and
+15.6kb DHS were all evident (13). We therefore
cannot rule out the possibility that looping of the CFTR
locus in primary epididymis cells is induced by interaction
of either the +7.0kb or the +15.6kb DHS with the
CFTR promoter. However, given that in other cell types
the presence of these DHS shows poor correlation with
CFTR expression, it seems highly likely that an important
role is performed by the +6.8kb DHS, which was only
observed in a subset of CFTR-expressing primary
cell types.
It seems probable that the induction and maintenance
of looping of the CFTR locus is dependent on the inter-
action of multiple regulatory elements located in diﬀerent
DHS regions, both intronic and ﬂanking the gene
(Figure 6). Indeed we now have evidence that several
intronic DHS also contribute to the loops (Ott et al.,
2008. Journal of Cellular and Molecular Medicine,
in Press). Hence, though a single element, such as that
within the DHS at the 30-end of the gene is unlikely to
be solely responsible for the looping phenomenon, it may
play a pivotal role in primary epididymis. We predict a co-
ordinated interplay of the regulatory elements located
within DHS at the 30-end of the CFTR gene and note
similarities between this cluster of DHS and the human
 -globin locus control region (LCR) (41): (i) Both com-
prise ﬁve DHS (+5.4kb, +6.8kb, +7.0kb, +7.4kb and
+15.6kb in the case of CFTR;5 0HS1-5 in the case of
 -globin). In the case of the CFTR 30 region, these DHS
are spread over 11kb, while the  -globin LCR is about
16kb in size; (ii) both contain CTCF-binding elements
(+6.8kb DHS in the case of CFTR;5 0HS5 in the case
of  -globin); (iii) when their corresponding genes are
actively transcribed, both regions contain peaks of euchro-
matin-speciﬁc histone modiﬁcations (at the +15.6kb
DHS in the case of CFTR) (6); and (iv) both interact
with the promoters of their corresponding genes, inducing
genomic loops and the formation of an ACH. Future
experiments will determine whether the DHS cluster 30
to CFTR does indeed represent an LCR. Understanding
the precise mechanisms by which CFTR expression is
regulated is likely to be of direct practical relevance
in the design of eﬀective gene therapy vectors for
cystic ﬁbrosis.
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